sorafenib has been researched along with ctx-0294885 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ctx-0294885) | Trials (ctx-0294885) | Recent Studies (post-2010) (ctx-0294885) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 5 | 0 | 5 |
| Protein | Taxonomy | sorafenib (IC50) | ctx-0294885 (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | 0.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abu Rabah, RR; Al Shamma, SA; Al-Tel, TH; Anbar, HS; El-Gamal, MI; Elgendy, SM; Omar, HA; Sebastian, A; Shehata, MK; Sultan, S; Tarazi, H; Vunnam, S; Zaraei, SO | 1 |
1 other study(ies) available for sorafenib and ctx-0294885
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2022 |